Author Correction: SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Saved in:
| Main Authors: | Birdie Huang, Chieh-Li Yen, Chao-Yi Wu, Chung-Ying Tsai, Jia-Jin Chen, Ching-Chung Hsiao, Yung-Chang Chen, I-Chang Hsieh, Huang-Yu Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-96996-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01) -
Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01) -
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
by: Tushar Tarun, et al.
Published: (2024-06-01) -
Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study
by: Allen Cheng-Wei Li, et al.
Published: (2025-01-01) -
Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study.
by: Allen Cheng-Wei Li, et al.
Published: (2025-01-01)